Aravive (Aravive) FCF Margin % : -355.88% (As of Sep. 2023)

View and export this data going back to 2014. Start your Free Trial

What is Aravive FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Aravive's Free Cash Flow for the three months ended in Sep. 2023 was $-9.81 Mil. Aravive's Revenue for the three months ended in Sep. 2023 was $2.76 Mil. Therefore, Aravive's FCF Margin % for the quarter that ended in Sep. 2023 was -355.88%.

As of today, Aravive's current FCF Yield % is -2,015.32%.

The historical rank and industry rank for Aravive's FCF Margin % or its related term are showing as below:

ARAV' s FCF Margin % Range Over the Past 10 Years
Min: -2287.82 Med: -395.87 Max: -214.05
Current: -849.92

During the past 11 years, the highest FCF Margin % of Aravive was -214.05%. The lowest was -2287.82%. And the median was -395.87%.

ARAV's FCF Margin % is not ranked
in the Biotechnology industry.
Industry Median: -148.935 vs ARAV: -849.92

Aravive FCF Margin % Historical Data

The historical data trend for Aravive's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Aravive FCF Margin % Chart

Aravive Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

FCF Margin %

Get a 7-Day Free Trial

-2,287.82

-359.37

-214.05

-432.37

-712.38

Aravive Quarterly Data
	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23
FCF Margin %	Get a 7-Day Free Trial															-382.00	-965.81	-1,190.61	-1,385.87	-355.88

Competitive Comparison of Aravive's FCF Margin %

For the Biotechnology subindustry, Aravive's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Aravive's FCF Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Aravive's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Aravive's FCF Margin % falls into.

Aravive FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Aravive's FCF Margin for the fiscal year that ended in Dec. 2022 is calculated as

FCF Margin	=	Free Cash Flow (A: Dec. 2022 )	/	Revenue (A: Dec. 2022 )
	=	-65.09	/	9.137
	=	-712.38 %

Aravive's FCF Margin for the quarter that ended in Sep. 2023 is calculated as

FCF Margin	=	Free Cash Flow (Q: Sep. 2023 )	/	Revenue (Q: Sep. 2023 )
	=	-9.808	/	2.756
	=	-355.88 %

Aravive FCF Margin % Related Terms

Thank you for viewing the detailed overview of Aravive's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Aravive (Aravive) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Aravive Inc (NAS:ARAV) » Definitions » FCF Margin %

Comparable Companies

Traded in Other Exchanges

VE11:Germany VE11:Germany

Address

3730 Kirby Drive, River Oaks Tower, Suite 1200, Houston, TX, USA, 77098

Website

https://www.aravive.com

Aravive Inc is a clinical-stage biopharmaceutical company. It focuses on developing treatments designed to halt the progression of life-threatening diseases, including cancer and fibrosis. The company pipeline product Batiraxcept (formerly AVB-500) which is an ultra-high affinity decoy protein that binds to GAS6 and thereby prevents AXL signaling to inhibit metastasis and tumor growth and restore sensitivity to anti-cancer agents. Batiraxcept is currently being evaluated in multiple clinical trials.

Executives

Maria Carolina Petrini	officer: Chief Commercial Officer	RIVER OAKS TOWER, 3730 KIRBY DRIVE, SUITE 1200, HOUSTON TX 77098
Robert B. Geller	officer: Chief Medical Officer	RIVER OAKS TOWER, 3730 KIRBY DRIVE, SUITE 1200, HOUSTON TX 77098
Rudy Howard	officer: Chief Financial Officer	322 WINDCHASE LANE, WILMINGTON NC 28409
Leonard Scott Dove	officer: Chief Operating Officer	RIVER OAKS TOWER, 3730 KIRBY DRIVE, SUITE 1200, HOUSTON TX 77098
Amato Giaccia	director, 10 percent owner	C/O VERSARTIS, INC., 1020 MARSH ROAD, MENLO PARK CA 94025
Gail Frances Mcintyre	officer: Chief Scientific Officer	C/O FURIEX PHARMACEUTICALS, INC., 3900 PARAMOUNT PARKWAY, SUITE 150, MORRISVILLE NC 27560
John Hohneker	director	C/O DIMENSION THERAPEUTICS, INC., 840 MEMORIAL DRIVE 4TH FLOOR, CAMBRIDGE MA 02139
Sigurd Kirk	director	225 SUMMIT AVENUE, MONTVALE NJ 07645
Peter Tai-ching Ho	director	C/O EPIZYME, INC., 400 TECHNOLOGY SQUARE, 4TH FLOOR, CAMBRIDGE MA 02139
Vinay Shah	officer: Chief Financial Officer	C/O VERSARTIS, INC., 1020 MARSH ROAD, MENLO PARK CA 94025
Reshma Rangwala	officer: Chief Medical Officer	RIVER OAKS TOWER, 3730 KIRBY DRIVE, SUITE 1200, HOUSTON TX 77098
Michael W Rogers	director	C/O KERYX BIOPHARMACEUTICALS INC, ONE MARINA PARK DRIVE, BOSTON MA 02210
Eshelman Ventures, Llc	director	319 N. 3RD STREET, SUITE 301, WILMINGTON NC 28401
Fredric N Eshelman	director	PPD INC, 929 NORTH FRONT STREET, WILMINGTON NC 28401
Rekha Hemrajani	director, officer: President and CEO	3928 POINT EDEN WAY, HAYWARD CA 94545